CHF62.10
0.48% day before yesterday
SIX Swiss Exchange, Jul 11, 05:31 pm CET
ISIN
NL0011832936
Symbol
COPN
Sector
Industry

COSMO Pharmaceuticals Target price 2025 - Analyst rating & recommendation

COSMO Pharmaceuticals Classifications & Recommendation:

Buy
90%
Hold
10%

COSMO Pharmaceuticals Price Target

Target Price CHF98.94
Price CHF62.10
Potential
Number of Estimates 6
6 Analysts have issued a price target COSMO Pharmaceuticals 2026 . The average COSMO Pharmaceuticals target price is CHF98.94. This is higher than the current stock price. The highest price target is
CHF139.65 124.88%
register free of charge
, the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend COSMO Pharmaceuticals to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the COSMO Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the COSMO Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 248.41 203.46
187.54% 18.10%
EBITDA Margin 56.52% 40.61%
23,349.37% 28.14%
Net Margin 49.94% 44.22%
529.73% 11.46%

6 Analysts have issued a sales forecast COSMO Pharmaceuticals 2025 . The average COSMO Pharmaceuticals sales estimate is

CHF203m
Unlock
. This is
18.10% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF258m 3.90%
Unlock
, the lowest is
CHF94.0m 62.16%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF248m 187.54%
2025
CHF203m 18.10%
Unlock
2026
CHF163m 19.65%
Unlock
2027
CHF133m 18.66%
Unlock
2028
CHF446m 235.78%
Unlock
2029
CHF690m 54.51%
Unlock
2030
CHF889m 28.91%
Unlock
2031
CHF920m 3.50%
Unlock
2032
CHF1.2b 29.29%
Unlock

5 Analysts have issued an COSMO Pharmaceuticals EBITDA forecast 2025. The average COSMO Pharmaceuticals EBITDA estimate is

CHF82.6m
Unlock
. This is
44.94% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF126m 15.96%
Unlock
, the lowest is
CHF41.1m 72.64%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF140m 66,952.38%
2025
CHF82.6m 41.14%
Unlock
2026
CHF73.1m 11.49%
Unlock
2027
CHF101m 37.66%
Unlock
2028
CHF270m 168.09%
Unlock
2029
CHF468m 73.22%
Unlock
2030
CHF629m 34.64%
Unlock
2031
CHF624m 0.87%
Unlock
2032
CHF858m 37.54%
Unlock

EBITDA Margin

2024 56.52% 23,349.37%
2025
40.61% 28.14%
Unlock
2026
44.73% 10.15%
Unlock
2027
75.71% 69.26%
Unlock
2028
60.45% 20.16%
Unlock
2029
67.77% 12.11%
Unlock
2030
70.78% 4.44%
Unlock
2031
67.79% 4.22%
Unlock
2032
72.12% 6.39%
Unlock

6 COSMO Pharmaceuticals Analysts have issued a net profit forecast 2025. The average COSMO Pharmaceuticals net profit estimate is

CHF90.0m
Unlock
. This is
27.48% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF106m 14.65%
Unlock
, the lowest is
CHF66.1m 46.74%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF124m 1,335.66%
2025
CHF90.0m 27.48%
Unlock
2026
CHF30.8m 65.72%
Unlock
2027
CHF44.6m 44.55%
Unlock
2028
CHF203m 355.34%
Unlock
2029
CHF354m 74.44%
Unlock
2030
CHF479m 35.31%
Unlock
2031
CHF475m 0.95%
Unlock
2032
CHF660m 39.07%
Unlock

Net Margin

2024 49.94% 529.73%
2025
44.22% 11.46%
Unlock
2026
18.86% 57.35%
Unlock
2027
33.53% 77.78%
Unlock
2028
45.47% 35.61%
Unlock
2029
51.33% 12.89%
Unlock
2030
53.88% 4.97%
Unlock
2031
51.56% 4.31%
Unlock
2032
55.46% 7.56%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF 7.58 5.62
1,322.58% 25.86%
P/E 11.06
EV/Sales 4.52

6 Analysts have issued a COSMO Pharmaceuticals forecast for earnings per share. The average COSMO Pharmaceuticals EPS is

CHF5.62
Unlock
. This is
24.77% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF6.61 11.51%
Unlock
, the lowest is
CHF4.12 44.85%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF7.58 1,322.58%
2025
CHF5.62 25.86%
Unlock
2026
CHF1.92 65.84%
Unlock
2027
CHF2.78 44.79%
Unlock
2028
CHF12.67 355.76%
Unlock
2029
CHF22.10 74.43%
Unlock
2030
CHF29.91 35.34%
Unlock
2031
CHF29.62 0.97%
Unlock
2032
CHF41.20 39.10%
Unlock

P/E ratio

Current 8.31 57.63%
2025
11.06 33.04%
Unlock
2026
32.26 191.68%
Unlock
2027
22.32 30.81%
Unlock
2028
4.90 78.05%
Unlock
2029
2.81 42.65%
Unlock
2030
2.08 25.98%
Unlock
2031
2.10 0.96%
Unlock
2032
1.51 28.10%
Unlock

Based on analysts' sales estimates for 2025, the COSMO Pharmaceuticals stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.70 43.94%
2025
4.52 22.16%
Unlock
2026
5.63 24.46%
Unlock
2027
6.92 22.95%
Unlock
2028
2.06 70.22%
Unlock
2029
1.33 35.28%
Unlock
2030
1.03 22.43%
Unlock
2031
1.00 3.37%
Unlock
2032
0.77 22.66%
Unlock

P/S ratio

Current 4.23 42.12%
2025
5.16 22.09%
Unlock
2026
6.43 24.46%
Unlock
2027
7.90 22.95%
Unlock
2028
2.35 70.22%
Unlock
2029
1.52 35.28%
Unlock
2030
1.18 22.43%
Unlock
2031
1.14 3.38%
Unlock
2032
0.88 22.66%
Unlock

Current COSMO Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Mar 31 2025
ODDO BHF
Locked
Locked
Locked Mar 06 2025
H.C. WAINWRIGHT & CO., LLC
Locked
Locked
Locked Jan 09 2025
BERENBERG
Locked
Locked
Locked Nov 18 2024
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Mar 31 2025
Locked
ODDO BHF:
Locked
Locked
Mar 06 2025
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
Locked
Jan 09 2025
Locked
BERENBERG:
Locked
Locked
Nov 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today